Key facts
- This page summarizes Douglas E. Williams's Form 4 filing for Codiak BioSciences, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Feb 2022, 15:05.
Douglas E. Williams - 16 Feb 2022 Form 4 Insider Report for Codiak BioSciences, Inc.
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 16 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2022, 15:05:58 UTC
- Prior SEC filing
- 21 Jan 2022
- Next SEC filing
- 21 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yalonda Howze, Attorney-in-Fact for Douglas E. Williams
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Douglas E. Williams filed Form 4 for Codiak BioSciences, Inc. on 18 Feb 2022.
Change
- Previous filing in this sequence was filed on 21 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CDAKQ
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +61,250
- Change %
- Price
- $0.000000
- Shares after
- 61,250
- Date
- 16 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 61,250
- Exercise price
- $5.21
- Footnotes
- F1
CDAKQ
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +91,875
- Change %
- Price
- $0.000000
- Shares after
- 91,875
- Date
- 16 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 91,875
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F3
On February 16, 2022, the reporting person was granted 91,875 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.